Skip to main content

Table 2 Percentages of different lymphocyte subsets in the CD4+ and CD8+ T cell population, in immune reconstitution inflammatory syndrome patients, clinical progressors and uninfected controls.

From: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: Beneficial effect of IL-2 and GM-CSF immunotherapy

  CD4 CD8  
  IRIS p value
HLA-DR 27.4 (16–38.4) 28.7 (24.6–32) < 0.005/n.s
CD38 77 (70–78.5) 82.6 (75.3–90.7) n.s/< 0.05
CD38 MFI 1118 (1253-780) 493 (548-297) < 0.02/< 0.01
Naïve 19.4 (6.9–23.9) 25 (7–42) < 0.005/n.s
Memory 85 (44–96) 53.8 (37.5–76) n.s/n.s
  CP  
HLA-DR 7.3 (5.4–9.2) 30.5 (22–40)  
CD38 66 (60.7–71.7) 73 (61.7–80)  
CD38 MFI 173 (85–211) 133 (105–146)  
Naïve 35 (30–45) 32 (24.6–42)  
Memory 59 (54–67) 38 (26–46)  
  UC  
HLA-DR 4 (2.8–5.3) 7.6 (6.9–9.9)  
CD38 70 (68–75.5) 66 (66–70)  
CD38 MFI 97 (71–116) 85 (58–87)  
Naïve 40.8 (40–49) 60.4 (51.2–61.5)  
Memory 30 (29.2–40) 22 (20.8–30.3)  
  1. IRIS- Immune reconstitution inflammatory syndrome patients; CP- asymptomatic clinical progressors; UC- uninfected controls. Data are shown as median percentage, and CD38 mean fluorescent intensity (MFI) (interquartile range). p values shown between IRIS and CP patients for CD4/CD8 data respectively.
\